Completed
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
NCT00000632
- Conditions
- Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
- Locations
-
- Univ. of Rochester AVEG Rochester, New York, United States
- Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
- UW - Seattle AVEG Seattle, Washington, United States